Reactions to learning a “not elevated” amyloid PET result in a preclinical Alzheimer’s disease trial

BACKGROUND: The experiences of biomarker-ineligible cognitively normal persons can inform trial conduct and the translation of preclinical Alzheimer’s disease (AD) into clinical practice. METHODS: We interviewed 33 persons whose “not elevated” brain amyloid imaging biomarker result made them ineligi...

Descripción completa

Detalles Bibliográficos
Autores principales: Grill, Joshua D., Cox, Chelsea G., Harkins, Kristin, Karlawish, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303934/
https://www.ncbi.nlm.nih.gov/pubmed/30579361
http://dx.doi.org/10.1186/s13195-018-0452-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303934/
https://www.ncbi.nlm.nih.gov/pubmed/30579361
http://dx.doi.org/10.1186/s13195-018-0452-1

Ejemplares similares